All In Biotech

Drug Trial Radar · NCT07880548

Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU Patients

Remimazolam Tosylate for Long-Term Sedation in Mechanically Ventilated ICU Patients: A Multicenter, Randomized, Propofol-Controlled, Non-Inferiority Study

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

274

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Jul 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, controlled, non-inferiority trial is designed to determine whether remimazolam is non-inferior to propofol for prolonged sedation in adult ICU patients requiring mechanical ventilation for ≥48 hours. A total of 274 patients will be enrolled across 21 geographically diverse hospitals in China and allocated in a 1:1 ratio to receive either remimazolam or propofol using centralized, computer-generated block randomization. The primary endpoint is time to successful extubation-defined as extubation without reintubation within 48 hours. Secondary endpoints include quantitative measures of sedation quality (e.g., RASS, time to target sedation), clinically outcomes (e.g., length of ICU stay, 28-day and 90-day all-cause mortality), and comprehensive safety evaluation (e.g., incidence and severity of hypotension, post-sedation delirium).

Conditions

  • Long-term Sedation for Mechanical Ventilation
  • Critically Ill Intensive Care Unit Patients

Interventions

  • Remimazolam groupDrug

    Remimazolam tosilate injection by IV infusion: loading dose 0.05-0.10 mg/kg over ≥ 1 min, then maintenance starting at 0.2 mg/kg/h, titrated in 0.1-0.2 mg/kg/h to achieve the target depth of sedation RASS -2 to +1; maintenance range 0-2 mg/kg/h; up to 28 days of study drug treatment.

  • Propofol groupDrug

    Propofol by IV infusion: loading dose 0.3-0.5 mg/kg over ≥ 1 min, then maintenance starting at 0.3 mg/kg/h, titrated in 0.3-0.6 mg/kg/h to achieve the target depth of sedation RASS -2 to +1; maintenance range 0-4 mg/kg/h; up to 28 days of study drug treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to successful extubationTime frame: From randomization to 28 days after randomization

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • Longgang Central Hospital of Shenzhen

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Wuhan Third Hospital · Tongren Hospital of Wuhan University

    Wuhan, Hubei, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Qinghai University Affiliated Hospital

    Xining, Qinghai, China

  • Zibo Central Hospital

    Zibo, Shandong, China

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • Sichuan Mianyang 404 Hospital

    Mianyang, Sichuan, China

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China

  • Lishui Central Hospital

    Lishui, Zhejiang, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.